Letrozole versus human menopausal gonadotrophin in women undergoing intrauterine insemination

Aynur Baysoy, Hasan Serdaroglu, Hashim Jamal, Emre Karatekeli, Hakan Ozornek, Erkut Attar

    Research output: Contribution to journalArticle

    20 Citations (Scopus)

    Abstract

    This pilot study was conducted to compare the results of intrauterine insemination (IUI) under ovarian stimulation with either letrozole (Femara) or human menopausal gonadotrophin (HMG). A randomized controlled trial was conducted. Eighty women aged 20-35 years with unexplained infertility of at least 2 years' duration were randomized according to a computer-generated randomization list into the letrozole group and the HMG group. Letrozole was administered at 5 mg/day from day 3 to day 7 of the IUI cycle. HMG injections were started on day 3 at a dose of 75 IU for women under 30 years old and 150 IU for women over 30 years old and monitored periodically by vaginal ultrasound and oestradiol concentrations. The variables selected for analysis were clinical pregnancy rate, endometrial thickness, length of follicular phase and number of preovulatory follicles. No statistically significant difference in clinical pregnancy rates per cycle was found for patients in the letrozole or HMG group (18.4 versus 15.7%). Cost was significantly higher in the HMG stimulation cases (P < 0.001) and no injections were required in the letrozole group. In conclusion, letrozole offers a new treatment regimen in ovarian stimulation regimens for IUI that is cost effective, simple and convenient for the patients.

    Original languageEnglish
    Article number2334
    Pages (from-to)208-212
    Number of pages5
    JournalReproductive BioMedicine Online
    Volume13
    Issue number2
    Publication statusPublished - Aug 2006

    Fingerprint

    letrozole
    Menotropins
    Insemination
    Ovulation Induction
    Pregnancy Rate
    Costs and Cost Analysis
    Injections
    Follicular Phase
    Random Allocation
    Infertility
    Estradiol

    Keywords

    • Aromatase inhibitors
    • HMG
    • Intrauterine insemination

    ASJC Scopus subject areas

    • Obstetrics and Gynaecology

    Cite this

    Baysoy, A., Serdaroglu, H., Jamal, H., Karatekeli, E., Ozornek, H., & Attar, E. (2006). Letrozole versus human menopausal gonadotrophin in women undergoing intrauterine insemination. Reproductive BioMedicine Online, 13(2), 208-212. [2334].

    Letrozole versus human menopausal gonadotrophin in women undergoing intrauterine insemination. / Baysoy, Aynur; Serdaroglu, Hasan; Jamal, Hashim; Karatekeli, Emre; Ozornek, Hakan; Attar, Erkut.

    In: Reproductive BioMedicine Online, Vol. 13, No. 2, 2334, 08.2006, p. 208-212.

    Research output: Contribution to journalArticle

    Baysoy, A, Serdaroglu, H, Jamal, H, Karatekeli, E, Ozornek, H & Attar, E 2006, 'Letrozole versus human menopausal gonadotrophin in women undergoing intrauterine insemination', Reproductive BioMedicine Online, vol. 13, no. 2, 2334, pp. 208-212.
    Baysoy A, Serdaroglu H, Jamal H, Karatekeli E, Ozornek H, Attar E. Letrozole versus human menopausal gonadotrophin in women undergoing intrauterine insemination. Reproductive BioMedicine Online. 2006 Aug;13(2):208-212. 2334.
    Baysoy, Aynur ; Serdaroglu, Hasan ; Jamal, Hashim ; Karatekeli, Emre ; Ozornek, Hakan ; Attar, Erkut. / Letrozole versus human menopausal gonadotrophin in women undergoing intrauterine insemination. In: Reproductive BioMedicine Online. 2006 ; Vol. 13, No. 2. pp. 208-212.
    @article{3da93195a663410ab0d45d1d91ebcb14,
    title = "Letrozole versus human menopausal gonadotrophin in women undergoing intrauterine insemination",
    abstract = "This pilot study was conducted to compare the results of intrauterine insemination (IUI) under ovarian stimulation with either letrozole (Femara) or human menopausal gonadotrophin (HMG). A randomized controlled trial was conducted. Eighty women aged 20-35 years with unexplained infertility of at least 2 years' duration were randomized according to a computer-generated randomization list into the letrozole group and the HMG group. Letrozole was administered at 5 mg/day from day 3 to day 7 of the IUI cycle. HMG injections were started on day 3 at a dose of 75 IU for women under 30 years old and 150 IU for women over 30 years old and monitored periodically by vaginal ultrasound and oestradiol concentrations. The variables selected for analysis were clinical pregnancy rate, endometrial thickness, length of follicular phase and number of preovulatory follicles. No statistically significant difference in clinical pregnancy rates per cycle was found for patients in the letrozole or HMG group (18.4 versus 15.7{\%}). Cost was significantly higher in the HMG stimulation cases (P < 0.001) and no injections were required in the letrozole group. In conclusion, letrozole offers a new treatment regimen in ovarian stimulation regimens for IUI that is cost effective, simple and convenient for the patients.",
    keywords = "Aromatase inhibitors, HMG, Intrauterine insemination",
    author = "Aynur Baysoy and Hasan Serdaroglu and Hashim Jamal and Emre Karatekeli and Hakan Ozornek and Erkut Attar",
    year = "2006",
    month = "8",
    language = "English",
    volume = "13",
    pages = "208--212",
    journal = "Reproductive BioMedicine Online",
    issn = "1472-6483",
    publisher = "Elsevier",
    number = "2",

    }

    TY - JOUR

    T1 - Letrozole versus human menopausal gonadotrophin in women undergoing intrauterine insemination

    AU - Baysoy, Aynur

    AU - Serdaroglu, Hasan

    AU - Jamal, Hashim

    AU - Karatekeli, Emre

    AU - Ozornek, Hakan

    AU - Attar, Erkut

    PY - 2006/8

    Y1 - 2006/8

    N2 - This pilot study was conducted to compare the results of intrauterine insemination (IUI) under ovarian stimulation with either letrozole (Femara) or human menopausal gonadotrophin (HMG). A randomized controlled trial was conducted. Eighty women aged 20-35 years with unexplained infertility of at least 2 years' duration were randomized according to a computer-generated randomization list into the letrozole group and the HMG group. Letrozole was administered at 5 mg/day from day 3 to day 7 of the IUI cycle. HMG injections were started on day 3 at a dose of 75 IU for women under 30 years old and 150 IU for women over 30 years old and monitored periodically by vaginal ultrasound and oestradiol concentrations. The variables selected for analysis were clinical pregnancy rate, endometrial thickness, length of follicular phase and number of preovulatory follicles. No statistically significant difference in clinical pregnancy rates per cycle was found for patients in the letrozole or HMG group (18.4 versus 15.7%). Cost was significantly higher in the HMG stimulation cases (P < 0.001) and no injections were required in the letrozole group. In conclusion, letrozole offers a new treatment regimen in ovarian stimulation regimens for IUI that is cost effective, simple and convenient for the patients.

    AB - This pilot study was conducted to compare the results of intrauterine insemination (IUI) under ovarian stimulation with either letrozole (Femara) or human menopausal gonadotrophin (HMG). A randomized controlled trial was conducted. Eighty women aged 20-35 years with unexplained infertility of at least 2 years' duration were randomized according to a computer-generated randomization list into the letrozole group and the HMG group. Letrozole was administered at 5 mg/day from day 3 to day 7 of the IUI cycle. HMG injections were started on day 3 at a dose of 75 IU for women under 30 years old and 150 IU for women over 30 years old and monitored periodically by vaginal ultrasound and oestradiol concentrations. The variables selected for analysis were clinical pregnancy rate, endometrial thickness, length of follicular phase and number of preovulatory follicles. No statistically significant difference in clinical pregnancy rates per cycle was found for patients in the letrozole or HMG group (18.4 versus 15.7%). Cost was significantly higher in the HMG stimulation cases (P < 0.001) and no injections were required in the letrozole group. In conclusion, letrozole offers a new treatment regimen in ovarian stimulation regimens for IUI that is cost effective, simple and convenient for the patients.

    KW - Aromatase inhibitors

    KW - HMG

    KW - Intrauterine insemination

    UR - http://www.scopus.com/inward/record.url?scp=33747059579&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=33747059579&partnerID=8YFLogxK

    M3 - Article

    C2 - 16895634

    AN - SCOPUS:33747059579

    VL - 13

    SP - 208

    EP - 212

    JO - Reproductive BioMedicine Online

    JF - Reproductive BioMedicine Online

    SN - 1472-6483

    IS - 2

    M1 - 2334

    ER -